Athymic nude mouse model for the study of new antioestrogens in breast cancer

Breast

Volumn 5, Issue 3, 1996, Pages 181-185

  Osborne, C K ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ESTROGEN; ESTROGEN RECEPTOR; FULVESTRANT; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; BREAST CANCER; CANCER CONTROL; CONFERENCE PAPER; FEMALE; HORMONAL THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

EID: 0030037467     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9776(96)90090-9     Document Type: Conference Paper

References (20)

1. Saez R A, Osborne C K. Hormonal treatment of advanced breast cancer. In: Current Clinical Oncology. New York: Alan R Liss, 1989, 163-172.
2. Wiebe V J, Osborne C K, Fuqua S A W, DeGregofio M. Tamoxifen resistance in breast cancer. CRC Crit Rev Oncol/Hematol 1993; 14: 173-188.
3. Wakeling A E, Newboult E, Peters S W. Effects of antioestrogens on the proliferation of MCF-7 human breast cancer cells. J Mol Endocrinol 1989; 2: 225-234.
4. Wakeling A E, Duke M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res 1991; 51: 3867-3873.
5. Osborne C K, Hobbs K, Clark G M. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res 1985; 45: 584-590.
6. Osborne C K, Coronado E B, Robinson J P. Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy. Eur J Cancer Clin Oncol 1987; 23: 1189-1196.
7. DeGregorio M W, Wilbur B J, Coronado E, Osborne C K. Serum tamoxifen concentrations in the athymic nude mouse after three methods of administration. Cancer Chemother Pharmacol 1987; 20: 316-318.
8. Gottardis M M, Jordan V C. Development of tamoxifen-stimulated growth of MCF-7 tumours in athymic nude mice after long-term antiestrogen administration. Cancer Res 1988; 48: 5183-5187.
9. Osborne C K, Coronado-Heinsohn E B, Hilsenbeak S G et al. Comparison of the effects of a pure steroid antioestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 1995; 87: 746-750.
10. Osborne C K, Coronado E, Allred D C, Wiebe V, DeGregorio M. Acquired tamoxifen resistance: correlation with reduced tumour levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. J Natl Cancer Inst 1991; 83: 1477-1482.
11. Osborne C K, Jarman M, McCague R, Coronado E B, Hilsenbeck S G, Wakeling A E. The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth. Cancer Chemother Pharmacol 1994; 34: 89-95.
12. Encarnacion C A, Ciocca D R, McGuire W L, Clark G M, Fuqua S A W, Osborne C K. Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Treat 1993; 26: 237-246.
13. Taylor S G IV, Gelman R S, Falkson G et al. Combination chemotherapy compared to tamoxifen as initial therapy for stage IV breast cancer in elderly women. Ann Intern Med 1986; 104: 455-461.
14. Hoogstraten B, Gad-El-Mawla N, Maloney T R et al. Combined modality therapy for first recurrence of breast cancer. A Southwest Oncology Group Study. Cancer 1984; 54: 2248-2256.
15. Pritchard K I, Thomson D B, Myers R E et al. Tamoxifen therapy in premenopausal patients with metastatic breast cancer. Cancer Treat Rep 1980; 64: 787-796.
16. Gottardis M M, Jiang S Y, Jeng M H et al. Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res 1989; 49: 4090-4093.
17. Wiebe V J, Osborne C K, McGuire W L, DeGregorio M W. Identification of oestrogenic tamoxifen metabolite(s) in tamoxifen resistant human breast tumors. J Clin Oncol 1992; 10: 990-994.
18. Wolf D M, Langan-Fahey S M, Parker C J, McCague R, Jordan V C. Investigation of the mechanism of tamoxifen-stimulated breast tumor growth with nonisomerizable analogues of tamoxifen and metabolites. J Natl Cancer Inst 1993; 85: 806-812.
19. DeFriend D J, Howell A, Nicholson R I et al. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res 1994; 54: 408-414.
20. Howell A, Defriend D, Robertson J, Blarney R, Walton P. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet 1995; 345: 29-30.